Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481166 | 1.00 | PTGS1 (0.50) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL3681089 | 1.00 | PTGS1 (0.50) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL6045489 | 0.93 | GRM8 (0.56) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL6119573 | 0.93 | GRM8 (0.56) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL8505283 | 0.93 | GRM8 (0.56) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL3681093 | 0.90 | BLM (0.48) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL16203683 | 0.89 | PTGS1 (0.56) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL22316501 | 0.85 | PTGS1 (0.58) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL22111145 | 0.85 | PTGS1 (0.58) | PTGS1GSTK1DPP4DPP8DPP9 | |
| SCHEMBL29526128 | 0.85 | PTGS1 (0.51) | PTGS1GSTK1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724061-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724068-A2 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20250064991-A1 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | claimed |
| US-20250032650-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2025-01-30 | — | — | US | claimed |
| WO-2024254479-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2024-12-12 | — | — | WO | claimed |
| WO-2024254417-A2 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2024-12-12 | — | — | WO | claimed |
| EP-4444301-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| EP-4444292-A1 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023108009-A1 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | claimed |
| WO-2023108031-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | CYTOSITE BIOPHARMA INC. (US) | 2023-06-15 | — | — | WO | claimed |
| CN-111171135-B | Glucagon-derived peptides with dual receptor agonism and uses thereof | 天津药物研究院有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-112753990-B | Natural flavor base material and preparation method and application thereof | 佛山市海天(高明)调味食品有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-113956348-A | Glucagon and GLP-1 co-agonist compounds | 伊莱利利公司 | 2022-01-21 | — | — | CN | claimed |
| EP-4724061-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724068-A2 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551582-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2026-02-17 | — | — | US | disclosed |
| WO-1984004931-A1 | METHOD AND COMPOSITION FOR DETERMINATION OF GAMMA GLUTAMYL TRANSPEPTIDASE | COULTER ELECTRONICS (US) | 1984-12-20 | — | — | WO | disclosed |
| EP-0018628-A1 | Method of determining gamma-glutamyl transpeptidase | BEHRINGWERKE Aktiengesellschaft (DE) | 1980-11-12 | — | — | EP | disclosed |
| US-4049702-A | DIAGNOSIS OF LIVER DISEASE BY DETERMINATION OF G-GLUTAMYL-TRANS-PEPTIDASE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1977-09-20 | — | — | US | disclosed |
| US-3979447-A | DETERMINATION OF G-GLUTAMYLTRANSPEPTIDASE | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064991-A1 | COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | GZMB, PRF1, CTSB | PTGS1 1969/4885GSTK1 610/4885DPP4 1119/4885 |
| US-20250032650-A1 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | GZMB, PRF1, CTSB | PTGS1 1292/4885GSTK1 597/4885DPP4 1139/4885 |
| US-12551582-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | PTGS1 2021/4885GSTK1 3292/4885DPP4 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.